vs
Side-by-side financial comparison of American Tower (AMT) and Biogen (BIIB). Click either name above to swap in a different company.
American Tower is the larger business by last-quarter revenue ($2.7B vs $2.3B, roughly 1.2× Biogen). American Tower runs the higher net margin — 110.1% vs -2.1%, a 112.3% gap on every dollar of revenue. On growth, American Tower posted the faster year-over-year revenue change (6.8% vs -7.1%). American Tower produced more free cash flow last quarter ($941.0M vs $468.0M). Over the past eight quarters, American Tower's revenue compounded faster (3.7% CAGR vs -0.2%).
American Tower Corporation, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of approximately 219,000 communications sites. For more information about American Tower, please visit the Earnings Materials and Investor Presentations sections of our investor relations website at www.americantower.com.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
AMT vs BIIB — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.7B | $2.3B |
| Net Profit | $3.0B | $-48.9M |
| Gross Margin | — | 78.3% |
| Operating Margin | 0.0% | -2.5% |
| Net Margin | 110.1% | -2.1% |
| Revenue YoY | 6.8% | -7.1% |
| Net Profit YoY | -2.6% | -118.3% |
| EPS (diluted) | — | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $2.3B | ||
| Q3 25 | $2.7B | $2.5B | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.6B | $2.4B | ||
| Q4 24 | $2.5B | $2.5B | ||
| Q3 24 | $2.5B | $2.5B | ||
| Q2 24 | $2.5B | $2.5B |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $836.8M | $-48.9M | ||
| Q3 25 | $912.6M | $466.5M | ||
| Q2 25 | $380.5M | $634.8M | ||
| Q1 25 | $498.6M | $240.5M | ||
| Q4 24 | $1.2B | $266.7M | ||
| Q3 24 | $-780.4M | $388.5M | ||
| Q2 24 | $908.4M | $583.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.3% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | — | 77.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 76.2% | ||
| Q3 24 | — | 74.1% | ||
| Q2 24 | — | 77.8% |
| Q1 26 | 0.0% | — | ||
| Q4 25 | 42.4% | -2.5% | ||
| Q3 25 | 45.4% | 22.0% | ||
| Q2 25 | 45.6% | 28.1% | ||
| Q1 25 | 48.9% | 12.8% | ||
| Q4 24 | 42.4% | 11.9% | ||
| Q3 24 | 45.2% | 18.3% | ||
| Q2 24 | 45.4% | 28.3% |
| Q1 26 | 110.1% | — | ||
| Q4 25 | 30.6% | -2.1% | ||
| Q3 25 | 33.6% | 18.4% | ||
| Q2 25 | 14.5% | 24.0% | ||
| Q1 25 | 19.5% | 9.9% | ||
| Q4 24 | 48.3% | 10.9% | ||
| Q3 24 | -30.9% | 15.8% | ||
| Q2 24 | 35.7% | 23.7% |
| Q1 26 | — | — | ||
| Q4 25 | $1.76 | $-0.35 | ||
| Q3 25 | $1.82 | $3.17 | ||
| Q2 25 | $0.78 | $4.33 | ||
| Q1 25 | $1.04 | $1.64 | ||
| Q4 24 | $2.63 | $1.82 | ||
| Q3 24 | $-1.69 | $2.66 | ||
| Q2 24 | $1.92 | $4.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | — |
| Total DebtLower is stronger | — | $6.3B |
| Stockholders' EquityBook value | $10.2B | $18.3B |
| Total Assets | — | $29.4B |
| Debt / EquityLower = less leverage | — | 0.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | $33.8B | $6.3B | ||
| Q3 25 | $34.9B | $6.3B | ||
| Q2 25 | $35.2B | $6.3B | ||
| Q1 25 | $34.0B | $4.5B | ||
| Q4 24 | $32.8B | $6.3B | ||
| Q3 24 | $33.4B | $4.5B | ||
| Q2 24 | $35.6B | $6.3B |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $3.7B | $18.3B | ||
| Q3 25 | $4.0B | $18.2B | ||
| Q2 25 | $3.7B | $17.6B | ||
| Q1 25 | $3.5B | $17.0B | ||
| Q4 24 | $3.4B | $16.7B | ||
| Q3 24 | $3.6B | $16.4B | ||
| Q2 24 | $3.9B | $15.9B |
| Q1 26 | — | — | ||
| Q4 25 | $63.2B | $29.4B | ||
| Q3 25 | $63.9B | $29.2B | ||
| Q2 25 | $63.8B | $28.3B | ||
| Q1 25 | $62.1B | $28.0B | ||
| Q4 24 | $61.1B | $28.0B | ||
| Q3 24 | $62.8B | $28.3B | ||
| Q2 24 | $65.8B | $26.8B |
| Q1 26 | — | — | ||
| Q4 25 | 9.26× | 0.34× | ||
| Q3 25 | 8.82× | 0.35× | ||
| Q2 25 | 9.48× | 0.36× | ||
| Q1 25 | 9.63× | 0.27× | ||
| Q4 24 | 9.70× | 0.38× | ||
| Q3 24 | 9.16× | 0.28× | ||
| Q2 24 | 9.24× | 0.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $511.9M |
| Free Cash FlowOCF − Capex | $941.0M | $468.0M |
| FCF MarginFCF / Revenue | 34.4% | 20.5% |
| Capex IntensityCapex / Revenue | 16.8% | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.7B | $2.1B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $5.5B | $511.9M | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.3B | $160.9M | ||
| Q1 25 | $1.3B | $259.3M | ||
| Q4 24 | $5.3B | $760.9M | ||
| Q3 24 | $1.5B | $935.6M | ||
| Q2 24 | $1.3B | $625.8M |
| Q1 26 | $941.0M | — | ||
| Q4 25 | $3.8B | $468.0M | ||
| Q3 25 | $994.5M | $1.2B | ||
| Q2 25 | $976.9M | $134.3M | ||
| Q1 25 | $963.9M | $222.2M | ||
| Q4 24 | $3.7B | $721.6M | ||
| Q3 24 | $1.0B | $900.6M | ||
| Q2 24 | $1.0B | $592.3M |
| Q1 26 | 34.4% | — | ||
| Q4 25 | 138.2% | 20.5% | ||
| Q3 25 | 36.6% | 48.4% | ||
| Q2 25 | 37.2% | 5.1% | ||
| Q1 25 | 37.6% | 9.1% | ||
| Q4 24 | 145.3% | 29.4% | ||
| Q3 24 | 41.4% | 36.5% | ||
| Q2 24 | 39.8% | 24.0% |
| Q1 26 | 16.8% | — | ||
| Q4 25 | 61.4% | 1.9% | ||
| Q3 25 | 17.1% | 1.8% | ||
| Q2 25 | 11.6% | 1.0% | ||
| Q1 25 | 12.9% | 1.5% | ||
| Q4 24 | 62.4% | 1.6% | ||
| Q3 24 | 16.8% | 1.4% | ||
| Q2 24 | 12.8% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.53× | — | ||
| Q3 25 | 1.60× | 2.73× | ||
| Q2 25 | 3.37× | 0.25× | ||
| Q1 25 | 2.60× | 1.08× | ||
| Q4 24 | 4.30× | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | 1.47× | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMT
Segment breakdown not available.
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
